DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Physostigmine (Physostigmine Salicylate) - Summary



Physostigmine Salicylate Injection is a derivative of the Calabar bean, and its active moiety, physostigmine, is also known as eserine.

Physostigmine Salicylate (physostigmine) is indicated for the following:

To reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome.

See all Physostigmine indications & dosage >>


Published Studies Related to Physostigmine

Anesthesia with 1.5 minimum alveolar concentration sevoflurane is not altered by physostigmine as measured by bispectral and clinical indices. [2005]
anesthesia and recovery... CONCLUSIONS: Physostigmine did not influence BIS values or early recovery when

Physostigmine for Alzheimer's disease. [2001]
CONCLUSIONS: The evidence of effectiveness of physostigmine for the

Physostigmine and cognition in schizotypal personality disorder. [2001]
There is evidence that reduced cholinergic activity may play a role in the pathophysiology of cognitive impairment in the schizophrenia spectrum. We tested the effects of physostigmine, an anticholinesterase inhibitor, on visuospatial working memory as evaluated by the Dot test, and on verbal learning and recall as measured by a serial learning task in patients with schizotypal personality disorder.

Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects. [2000]
electroencephalogram (EEG) by physostigmine compared to flumazenil and placebo... CONCLUSION: Physostigmine and flumazenil antagonized midazolam-induced sedation.

Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. [2000]
mild-to-moderate Alzheimer disease (AD) in a multicenter trial... CONCLUSIONS: Physostigmine demonstrated a statistically significant benefit

more studies >>

Clinical Trials Related to Physostigmine

Physostigmine After General Anesthesia [Recruiting]
Recovery after general anaesthesia is often prolonged in the elderly. This group is particularly exposed to post-operative confusion. This has negative personal consequences as well as consequences for the postoperative care for these patients. The hypothesis is that physostigmine will decrease the amount of time in the post-anaesthesia care unit (PACU ), the postoperative amount of pain and shivering and finally post-operative confusion.

The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy [Not yet recruiting]
The purpose of this study is to determine whether the administration of physostigmine in combination with sedation for colonoscopy can minimize the cognitive decline at the time of hospital discharge

Pilot Study of Physostigmine-Enhanced Opioid Analgesia [Completed]

Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery [Active, not recruiting]
Evaluation if physostigmine reduces symptoms in patients who has developed a delirium in Intensive care after a surgery

Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors [Recruiting]
The purpose of the study is to measure the sensitivity of NCFHEB binding to changes in endogenous acetylcholine levels in healthy smoking and nonsmoking subjects, and in schizophrenic smoking and nonsmoking subjects. We hypothesize that physostigmine-induced elevated ACh levels will lead to a reduction in the availability of nicotinic receptors for the binding of the radioligand. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects with schizophrenia, but the extent of this change will be different than in controls.

more trials >>

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017